{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:34:43Z","timestamp":1794836083347,"version":"4.9.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Swedish Kidney Foundation","award":["F2022-0084"],"award-info":[{"award-number":["F2022-0084"]}]},{"name":"Swedish Kidney Foundation","award":["F2021-0105"],"award-info":[{"award-number":["F2021-0105"]}]},{"name":"Swedish Heart and Lung Foundation","award":["20200766"],"award-info":[{"award-number":["20200766"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with chronic kidney disease (CKD) and atrial fibrillation (AF) on oral anticoagulants (OACs) are at high risk of bleeding. Determinants of major bleeding risk in OAC users with AF and CKD are not well established and available bleeding score systems do not perform well in CKD. This study aims to present risk factors associated with major bleeding in a Swedish cohort of OAC-treated patients with CKD G3\u20135D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a Swedish register-based cohort study including patients with AF and CKD G3\u20135D on warfarin or direct OACs (DOACs) between 2009 and 2018. Data were collected from high-quality registers including the Swedish Renal Registry and Auricula, a register for AF and OACs. Risk factors for major bleeding were investigated with Cox regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 2453 included patients, 59% were on warfarin (time in therapeutic range 67%) and 41% on DOACs. Major bleeding rates were 8.9\/100 patient-years. Factors associated with increased bleeding risk were glomerular filtration rate category, G5\/5D versus G3 {hazard ratio [HR] 1.92 [95% confidence interval (CI) 1.43\u20132.56]}, previous gastrointestinal bleeding [HR 1.77 (95% CI 1.39\u20132.25)], previous other bleeding [HR 1.33 (95% CI 1.09\u20131.62)], congestive heart failure [HR 1.36 (95% CI 1.11\u20131.68)], male sex [HR 1.28 (95% CI 1.03\u20131.60)] and vascular disease [HR 1.35 (95% CI 1.01\u20131.79)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with AF and G3\u20135D on OACs are at a high risk of bleeding. Previous major bleeding and kidney failure are strongly associated with major bleeding. The present study also shows an association between OAC-associated bleeding and male sex, congestive heart failure and vascular disease. Knowledge about determinants of bleeding in advanced CKD is essential when deciding on when to anticoagulate or not.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae206","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T08:01:25Z","timestamp":1720252885000},"source":"Crossref","is-referenced-by-count":13,"title":["Risk factors for major bleeding in patients with atrial fibrillation and CKD G3\u2013G5D on oral anticoagulants"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-7215","authenticated-orcid":false,"given":"Frida","family":"Welander","sequence":"first","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Department of Research and Development Sundsvall, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2141-6086","authenticated-orcid":false,"given":"Henrik","family":"Renlund","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Centre, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-1186","authenticated-orcid":false,"given":"Anders","family":"Sj\u00e4lander","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical medicine, Ume\u00e5 University , Ume\u00e5 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2024080809163314900_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080809163314900_bib2","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024080809163314900_bib3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2024080809163314900_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ckj\/sfad004","article-title":"Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3\u2013G5D","volume":"16","author":"Welander","year":"2023","journal-title":"Clin Kidney J"},{"key":"2024080809163314900_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study","volume":"83","author":"Fu","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2024080809163314900_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000166482","article-title":"Biochemical abnormalities of platelets in renal failure: evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase","volume":"1","author":"Eknoyan","year":"1981","journal-title":"Am J Nephrol"},{"key":"2024080809163314900_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0002-9343(85)90051-8","article-title":"Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis","volume":"79","author":"Di Minno","year":"1985","journal-title":"Am J Med"},{"key":"2024080809163314900_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/gft209","article-title":"Haemostasis in chronic kidney disease","volume":"29","author":"Lutz","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2024080809163314900_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"2024080809163314900_bib10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/eurheartj\/ehab059","article-title":"Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function","volume":"42","author":"de Jong","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080809163314900_bib11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ndt\/gfy387","article-title":"Performance of bleeding risk scores in dialysis patients","volume":"34","author":"Ocak","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2024080809163314900_bib12","article-title":"Annual Report 2023","author":"Swedish Renal Registry"},{"key":"2024080809163314900_bib13","article-title":"Annual Report 2018","author":"Auricula"},{"key":"2024080809163314900_bib14","article-title":"Annual report Riksstroke 2023","author":"Riksstroke"},{"key":"2024080809163314900_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2024080809163314900_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"2024080809163314900_bib17","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1093\/eurheartj\/ehaa650","article-title":"Nomenclature for kidney function and disease-executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference","volume":"41","author":"Levey","year":"2020","journal-title":"Eur Heart J"},{"key":"2024080809163314900_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2023.07.003","article-title":"Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3\u2013G5D","volume":"229","author":"Welander","year":"2023","journal-title":"Thromb Res"},{"key":"2024080809163314900_bib19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"key":"2024080809163314900_bib20","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jacep.2020.06.036","article-title":"Clinical outcomes of warfarin initiation in advanced chronic kidney disease patients with incident atrial fibrillation","volume":"6","author":"Agarwal","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2024080809163314900_bib21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2024080809163314900_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2024080809163314900_bib23","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"2024080809163314900_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2024080809163314900_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2019.10.013","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"221","author":"Garcia","year":"2020","journal-title":"Am Heart J"},{"key":"2024080809163314900_bib26","first-page":"3268","article-title":"Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial","volume":"36","author":"Vinereanu","year":"2015","journal-title":"Eur Heart J"},{"key":"2024080809163314900_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.phrs.2017.01.004","article-title":"Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): a systematic review and meta-analysis on gender differences","volume":"117","author":"Proietti","year":"2017","journal-title":"Pharmacol Res"},{"key":"2024080809163314900_bib28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00228-020-02856-6","article-title":"Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication","volume":"76","author":"Rydberg","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2024080809163314900_bib29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bj\u00f6rck","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024080809163314900_bib30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/jcm8081240","article-title":"Patients with heart failure and preserved ejection fraction are at risk of gastrointestinal bleeding","volume":"8","author":"Schrutka","year":"2019","journal-title":"J Clin Med"},{"key":"2024080809163314900_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae206\/58458264\/sfae206.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/8\/sfae206\/58770571\/sfae206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/8\/sfae206\/58770571\/sfae206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:11:44Z","timestamp":1723144304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae206\/7708367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae206","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,5]]},"article-number":"sfae206"}}